Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
Currus Biologics's investors include Brandon Capital, Uniseed, Brandon BioCatalyst, Medical Research Commercialisation Fund (MRCF).
Currus Biologics is headquartered in Melbourne, Australia.
Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
Currus Biologics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Currus Biologics — Funding & Investors." VCBacked, May 7, 2024, https://www.vcbacked.co/company/currus-biologics. Accessed September 30, 2026.
VCBacked. (2024). Currus Biologics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/currus-biologics
{{cite web |title=Currus Biologics — Funding & Investors |url=https://www.vcbacked.co/company/currus-biologics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated